Supercharge Your Innovation With Domain-Expert AI Agents!

Steroidal c- 17 benzoazoles

A composition and compound technology, applied in the direction of steroids, drug combinations, medical preparations containing active ingredients, etc.

Inactive Publication Date: 2013-10-16
UNIV OF MARYLAND BALTIMORE
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although, ketocamide is no longer used due to hepatotoxicity and other side effects, this suggests that more potent and alternative CYP17 inhibitors may become effective agents for the treatment of the disease, even in advanced stages and possible hormonal in resistant patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Steroidal c- 17 benzoazoles
  • Steroidal c- 17 benzoazoles
  • Steroidal c- 17 benzoazoles

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0073] biological research

[0074] CYP17 inhibition studies: The CYP17 inhibition coordination assay was done following our previously published procedure, where intact cytochrome P450cl7-expressing E. coli was used as the enzyme source (Grigoryev et al., "Cytochrome P450cl7-expressing Escherichia coli as a first-step screening system for 17[alpha]-hydroxylase-C17,20-lyase inhibitors", Anal.Biochem.;1999,267,319-330; and "Effects of new 17α-hydroxylase / C17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo", Br.J.Cancer, 1999, 81, 622-630. The IC of the compound 50 Values ​​were determined from dose-response curves and are listed in Table 1. Ketoconazole, IC of Abiraterone 50 values ​​(one CYP17 inhibitor in clinical trials (O'Donnell above), Chart 1) and 3β-hydroxy-17-(lH-imidazol-l-yl)androst-5,16-diene (VN / 85-1, compound 16, Diagram 1, is considered to be the most potent CYP17 inhibitor (Njar et al, mentioned above, Current Pharm.Design, 1999...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Described are steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic "addition-elimination" substitution reaction of 3²-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3²-ol or analogs thereof with tributylstannyl diazines. The compounds are potent inhibitors of human CYP 17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds are useful for the treatment of human prostate cancer.

Description

[0001] The patent application of the present invention is the international application number PCT / US2006 / 007143, the international application date is March 2, 2006, the application number entering the Chinese national phase is 200680006463.2, and the name is "new C-17-heteroaryl steroid CYP17 Inhibitor / Antiandrogen Substance: Its Synthesis, In Vitro Biological Activity, Pharmacokinetics and Antitumor Activity" is a divisional application of the invention patent application. technical field [0002] This application claims the priority date of US Provisional Application No. 60 / 657,390, filed March 2, 2005, which is incorporated herein by reference. [0003] The U.S. government has a fee-paid license to this invention, with the right, under limited circumstances, to request permission from the patentee for reasonable cause during the term granted by the National Institutes of Health (NIH) under grant number CA27440 others. [0004] The present invention provides novel chemica...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/58A61P35/00A61P13/08
CPCC07J43/003A61P13/08A61P35/00A61K31/58C07J43/00
Inventor A·布罗迪V·恩雅
Owner UNIV OF MARYLAND BALTIMORE
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com